European Commission approves Roche ’s first-in-class bispecific antibody Lunsumio for people with relapsed or refractory follicular lymphoma

Lunsumio® (mosunetuzumab) is the first CD20xCD3 T-cell engaging bispecific antibody available to treat the most common slow-growing form of non-Hodgkin lymphoma, follicular lymphoma (FL)Lunsumio represents a new type of immunotherapy that is a chemotherapy-free, off-the-shelf, fixed-duration treatment option that could improve outcomes for people who have relapsed or are refractory to multiple previous treatmentsApproval is based on the phase I/II GO29781 study, whereLunsumio induced high complete response rates, with the majority of complete responses lasting for at least 18 months in people with heavily pre-treated FLBasel, 8 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for the CD20xCD3 T-cell engaging bispecific antibody Lunsumio ® (mosunetuzumab), for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least two prior systemic therapies. Lunsumio is an off-the-shelf therapy that is readily available, so people do not have to wait to start treatment.Each year, more than 28,000 people in Europe are diagnosed withFL, which accounts for approximately one in five non-Hodgkin lymphoma cases.1,2 Despite treatment advances, FL is considered an incurable disease and relapse is common, with outcomes worsening on each consecutive treatment.1“We are delighted that Lunsumio is the first bispecific antibody approved in Europe for...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news